Business
Electromedical Technologies Reports Comparative 48% Revenue Growth for June 2021 Quarter
Electromedical Technologies Reports Comparative 48% Revenue Growth for June 2021 Quarter.
About this update from Electromedical Technologies, Inc.
[{"type":"text","content":"\n\n\n\nElectromedical Technologies Reports Comparative 48% Revenue Growth for June 2021 Quarter\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nElectromedical Technologies Reports Comparative 48% Revenue Growth for June 2021 Quarter\nResults demonstrate that new marketing initiatives are achieving company objectives\nPR Newswire\nSCOTTSDALE, Ariz., Aug. 18, 2021\n\n\n\nSCOTTSDALE, Ariz., Aug. 18, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the \"Company\"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it recorded strong results for the second quarter of 2021, ending June 30, as compared to the same period in 2020.\nQuarter ended June 2021 Highlights:\nRevenue increased to $202,954, up from $136,755, a roughly 48% increase over 2Q 2020. Selling, General, and Administrative expenses declined by approximately $259,000, to $677,781, down 28% from the $936,669 recorded in 2Q 2020. Net loss from operations was ($524,658) versus ($817,909) in 2Q 2020. Total net loss improved to ($774,532), or ($0.02) per share, from ($840,255), or ($0.04), for 2Q 2020. Matthew Wolfson, Founder and CEO of EMED, noted, \"We are pleased with our strong operating results for the second quarter of 2021. Implementation of our new sales and marketing initiatives, are starting to pay off as indicated by the significant increases in both unit sales and revenue. We will continue to emphasize these initiatives going forward, which could provide an enhanced foundation for our outreach efforts, potentially resulting in repeat orders from our partners and distributors.\" \n\"Separately, as year-end approaches, our team plans to update shareholders regarding our progress with the development of the WellnessProPlus POD which is a critical pending milestone for EMED.\" \nSix Months ended June 30, 2021 Highlights\nRevenue increased to $369,394 up from $351,625, a roughly 5% increase over the six months ended June 30, 2020. S...